麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病心绞痛的药物经济学评价OA
A Pharmacoeconomic Evaluation of Shexiang Baoxin Pills and Tongxinluo Capsule in the Treatment of Coronary Atherosclerotic Cardiopathy Angina Pectoris
目的 评价麝香保心丸与通心络胶囊治疗冠状动脉粥样硬化性心脏病(CHD)心绞痛的成本-效果.方法 检索国内外涉及麝香保心丸对比通心络胶囊治疗CHD心绞痛随机对照试验的相关已发表文献,经过筛选后进行质量评价,并采用Stata 16.0 统计软件进行荟萃分析.此外,参考我国各省市区挂网药物价格并结合用药量来计算成本,进一步分析成本-效果比.结果 最终纳入文献11 篇,涉及受试者990 例.与通心络胶囊相比,麝香保心丸症状有效率相差9%(95%CI:-5%～21%,P=0.23),心电图有效率相差 12%(95%CI:1%～23%,P=0.03),表明麝香保心丸的症状有效率和心电图有效率优于通心络胶囊.基于全国平均情况进行增量成本-效果比分析,与通心络胶囊比较,麝香保心丸在改善临床症状方面的增量成本-效果比为-285.26,表明麝香保心丸更具经济性;敏感性分析结果显示,在全国大部分省市区与通心络胶囊相比,麝香保心丸在改善临床症状方面的增量成本-效果比均为负数,提示麝香保心丸具有显著的经济学优势.在全国范围内,麝香保心丸与通心络胶囊相比,在改善心电图结果方面的增量成本-效果比为-570.53,麝香保心丸表现出绝对的经济性优势;敏感性分析结果显示,在全国大部分省市区麝香保心丸与通心络胶囊相比,在改善心电图结果方面的增量成本-效果比均为负数,同样证明了麝香保心丸更具绝对经济性.结论 在CHD心绞痛的临床治疗中,麝香保心丸在改善临床症状和心电图结果方面的效果均优于通心络胶囊,且在全国大部分省市区,麝香保心丸相比通心络胶囊具有绝对的经济性.
Objective To evaluate the cost-effectiveness of Shexiang Baoxin Pill and Tongxinluo capsule in the treatment of coronary atherosclerotic heart disease(CHD)angina pectoris.Methods Randomized controlled trials involving Shexiang Baoxin Pill versus Tongxinluo capsule in the treatment of CHD angina pectoris at home and abroad were searched.Quality evaluation was conducted after screening,and meta-analysis was performed using Stata 16.0 statistical software.In addition,the cost is calculated by referring to the drug price of various provinces and autonomous regions in China and combining with the drug quantity,and the cost-effectiveness ratio is further analyzed.Results Finally,11 literatures were included,involving 990 subjects.Compared with Tongxinluo capsule,the symptom effective rate of Shexiangbaoxin Pill was 9%(95%CI:-5%～21%,P=0.23),and the electrocardiogram effective rate was 12%(95%CI:1%～23%,P=0.03),indicating that the symptom effective rate and electrocardiogram effective rate of Shexiangbaoxin Pill were better than that of Tongxinluo capsule.Based on the national average situation,the incremental cost-effectiveness ratio was analyzed.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was-285.26,indicating that Shexiang Baoxin Pill was more economical.The results of sensitivity analysis showed that compared with Tongxinluo capsule in most provinces and autonomous regions of China,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving clinical symptoms was negative,suggesting that Shexiang Baoxin Pill has a significant economic advantage.Compared with Tongxinluo capsule,the incremental cost-effectiveness ratio of Shexiang Baoxin Pill in improving ECG results was-570.53,indicating that Shexiang Baoxin Pill showed absolute economic advantage.The results of sensitivity analysis showed that the incremental cost-effectiveness ratio of Shexiang Baoxin Pill to Tongxinluo capsule in improving ECG results was negative in most provinces and autonomous regions of China,which also proved that Shexiang Baoxin Pill was more economical.Conclusion In the clinical treatment of CHD angina pectoris,Shexiang Baoxin Pill is superior to Tongxinluo capsule in improving clinical symptoms and electrocardiogram results,and in most provinces and autonomous regions of China,Shexiang Baoxin Pill has absolute economy compared with Tongxinluo capsule.
王志军;吕冬梅;张桂娟;高志成;陈小菲;李勇
华北理工大学附属医院心内科,河北唐山 063000
临床医学
麝香保心丸通心络胶囊冠状动脉粥样硬化性心脏病心绞痛药物经济学
Shexiang Baoxin PillsTongxinluo capsuleCoronary atherosclerotic cardiopathyAngina pectorisPharmacoeconomics
《中国药物经济学》 2024 (008)
30-37,43 / 9
评论